Referencia número: HY-120501

B022

19 Cited Publications

Revisión del cliente

Based on 19 publication(s) in Google Scholar

B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (K_i of 4.2 nM; IC₅₀=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury. B022 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.27%
No. CAS: 1202764-53-1
Fòrmula: C₁₉H₁₆ClN₅OS
Peso molecular:397.88

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

B022 Chemical Structure

No. CAS: 1202764-53-1

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (19)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (K_i of 4.2 nM; IC₅₀=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury^[1]^[2]. B022 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

IC₅₀ & Target

Ki: 4.2 nM (NF-κB-inducing kinase (NIK))^[1]

Ver todos los productos específicos de isoformas NF-κB :

Cellular Effect

Cell Line	Type	Value	Description	References
Macrophage	IC₅₀	58.6 μM Compound: B022	Anti-inflammatory activity in mouse macrophages extracted from abdominal activity assessed as inhibition of LPS-induced nitric oxide production at 1 uM measured after 22 hrs by Griess reagent assay relative to control Anti-inflammatory activity in mouse macrophages extracted from abdominal activity assessed as inhibition of LPS-induced nitric oxide production at 1 uM measured after 22 hrs by Griess reagent assay relative to control	[PMID: 38563549]

In Vitro

B022 (0-5 μM; 12 hours; Hepa1 cells) treatment suppresses NIK-induced p52 formation in a dose-dependent manner^[1].
B022 (0-5 μM; 12 hours; Hepa1 cells) treatment for 8 h completely blocks NIK-induced expression of TNF-a, IL-6, iNOS, CCL2, and CXCL5^[1].
B022 prevents NIK- or H2O2-induced β cell death and also ameliorates streptozotocin (STZ)-induced β cell death and hyperglycemia^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Hepa1 cells
Concentration:

0 μM, 0.5 μM, 5 μM
Incubation Time:

12 hours
Result:

Suppressed NIK-induced p52 formation in a dose-dependent manner.

RT-PCR^[1]

Cell Line:

Hepa1 cells
Concentration:

0 μM, 0.5 μM, 5 μM
Incubation Time:

12 hours
Result:

Dose-dependently blocked NIK-induced expression of chemokines, cytokines, and iNOS in these cells. Completely blocked NIK-induced expression of TNF-a, IL-6, iNOS, CCL2, and CXCL5.

In Vivo

B022 (30 mg/kg; intravenous injection; twice a day; for 10 days; STOP-NIK male mice) treatment inhibits NIK-triggered liver inflammation and injury in STOP-NIK mice infected with cre adenoviruses^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

STOP-NIK male mice (8 weeks) infected with Ad-cre^[1]
Dosage:

30 mg/kg
Administration:

Intravenous injection; twice a day; for 10 days
Result:

Completely prevents the lethal effect of abnormally high levels of hepatic NIK in mice. Inhibited the majority of the deteriorating effects of aberrant activation of hepatic NIK.

Chemical Information

No. CAS 1202764-53-1
Appearance Solid
Peso molecular 397.88
Fòrmula C₁₉H₁₆ClN₅OS
Color Light yellow to yellow
SMILES

CC(C1=NC=CS1)(C#CC2=CC3=C(CCN3C4=NC(N)=NC=C4Cl)C=C2)O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (19)

All Flow CytometryCell Proliferation/Viability AssayWBIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signalling. [Abstract]

2025 Oct 3;10(1):326. PMID: 41038866
Immunity

Splenic TNF-α signaling potentiates the innate-to-adaptive transition of antiviral NK cells. [Abstract]

2025 Mar 11;58(3):585-600.e6. PMID: 40023159
Nat Commun

Hepatic neddylation deficiency triggers fatal liver injury via inducing NF-κB-inducing kinase in mice. [Abstract]

2022 Dec 16;13(1):7782. PMID: 36526632

B022 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Dec 16;13(1):7782. [Abstract]

B022 (5 µM; 48 h) significantly attenuates MLN-induced aberrant NIK signaling in HepG2 cells. Veh (black), B022 (blue).
Nat Commun

IL-33 induces thymic involution-associated naive T cell aging and impairs host control of severe infection. [Abstract]

2022 Nov 12;13(1):6881. PMID: 36371464
Cell Death Differ

LUBAC enables tumor-promoting LTβ receptor signaling by activating canonical NF-κB. [Abstract]

2024 Oct;31(10):1267-1284. PMID: 39215104
Adv Sci (Weinh)

Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. [Abstract]

2026 Apr;13(21):e18975. PMID: 41655233
J Neuroinflammation

TLR9/NF-κB-mediated dendritic cell activation by neutrophil extracellular traps drives pathogenesis in experimental cerebral malaria. [Abstract]

2025 Aug 26;22(1):206. PMID: 40859255

B022 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Aug 26;22(1):206. [Abstract]

Representative MFI histograms of CD86, CD80, and CD40 expression in BMDC, BMDC + NETs, BMDC + NETs + BAY 11-7082, and BMDC + NETs + B022 (5 µM) groups.

B022 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Aug 26;22(1):206. [Abstract]

Immunoblot analysis was performed on IκBα, P65 and p-P65 in the BMDC, BMDC + NETs, BMDC + NETs + BAY 11-7082 and BMDC + NETs + B022 (5 µM) groups.
J Neuroinflammation

Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis. [Abstract]

2025 Jan 24;22(1):17. PMID: 39856699

B022 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Jan 24;22(1):17. [Abstract]

Cell viability under different concentrations of B022 was detected using the CCK-8 assay.

B022 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Jan 24;22(1):17. [Abstract]

Mean fluorescence intensity (MFI) of CD80 and CD86 in the culture medium group and the B022 group (1000 nM).

B022 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Jan 24;22(1):17. [Abstract]

B022 (30 mg/kg; ip). Immunofluorescence staining of neuromuscular junction structures, specifically acetylcholine receptor clusters (green) and complement deposits C5b-9 (red).
Am J Transplant

Electrostimulation suppresses allograft rejection via promoting lymphatic regulatory T cell migration mediated by lymphotoxin - lymphotoxin receptor β signaling. [Abstract]

2024 Jul 9:S1600-6135(24)00392-7. PMID: 38992495
Liver Int

Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. [Abstract]

2024 Nov;44(11):2950-2963. PMID: 39164890
Int J Pharm

Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway. [Abstract]

2022 Nov 25:628:122361. PMID: 36332828
Inflammation

ACE2 Alleviates Microglia Neuroinflammation by RANK-RANKL-OPG Axis in Parkinson's Disease. [Abstract]

2025 Jul 5. PMID: 40615762
Int J Mol Sci

MK2/p38/p53 Suppress Basal IL-1β and Non-Canonical NF-κB Signaling in Macrophages. [Abstract]

2026 Apr 2;27(7):3232. PMID: 41977413
Biochim Biophys Acta Mol Basis Dis

LRRC8A as a central mediator promotes colon cancer metastasis by regulating PIP5K1B/PIP2 pathway. [Abstract]

2024 Feb 11;1870(4):167066. PMID: 38350542
Res Sq

2026 Apr 10.
University of Bonn

2025.
bioRxiv

2025 Oct 1.
bioRxiv

2025 Jan 1.
University of North Carolina at Chapel Hill

2024.

Solvente y solubilidad

In Vitro:

DMSO : 250 mg/mL (628.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5133 mL

12.5666 mL

25.1332 mL

5 mM

0.5027 mL

2.5133 mL

5.0266 mL

10 mM

0.2513 mL

1.2567 mL

2.5133 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 45% PEG300 5% Tween-80 50% Saline

Solubility: 1 mg/mL (2.51 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (280 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Ren X, et al. A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury. FASEB J. 2017 Feb;31(2):711-718. [Content Brief]

[2]. Li Z, et al. Discovery of a Potent and Selective NF-κB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo. J Med Chem. 2020;63(8):4388-4407. [Content Brief]

[3]. Li X, et al. Activation of NF-κB-Inducing Kinase in Islet β Cells Causes β Cell Failure and Diabetes. Mol Ther. 2020;28(11):2430-2441. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5133 mL	12.5666 mL	25.1332 mL	62.8330 mL
	5 mM	0.5027 mL	2.5133 mL	5.0266 mL	12.5666 mL
	10 mM	0.2513 mL	1.2567 mL	2.5133 mL	6.2833 mL
	15 mM	0.1676 mL	0.8378 mL	1.6755 mL	4.1889 mL
	20 mM	0.1257 mL	0.6283 mL	1.2567 mL	3.1417 mL
	25 mM	0.1005 mL	0.5027 mL	1.0053 mL	2.5133 mL
	30 mM	0.0838 mL	0.4189 mL	0.8378 mL	2.0944 mL
	40 mM	0.0628 mL	0.3142 mL	0.6283 mL	1.5708 mL
	50 mM	0.0503 mL	0.2513 mL	0.5027 mL	1.2567 mL
	60 mM	0.0419 mL	0.2094 mL	0.4189 mL	1.0472 mL
	80 mM	0.0314 mL	0.1571 mL	0.3142 mL	0.7854 mL
	100 mM	0.0251 mL	0.1257 mL	0.2513 mL	0.6283 mL

Keywords

B022

19 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

B022

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) B022

Ver todos los productos específicos de isoformas NF-κB

Actividad biológica

Chemical Information

Publications (19)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

B022 Related Classifications

HY-120501 Related Classifications